1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Fast-Track Loss For GSK's Dostarlimab

 
• By Maureen Kenny

GSK’s potential endometrial cancer treatment dostarlimab is one of two products to revert to standard review timelines in recent weeks.

Timer
The EMA now wants more time to review the MAA for dostarlimab • Source: Shutterstock

GlaxoSmithKline plc’s dostarlimab has lost its accelerated assessment status at the European Medicines Agency. The marketing authorization application for endometrial cancer will now be reviewed under standard timelines.

Dostarlimab is under development for the treatment of patients with recurrent or advanced mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Health Chief Declares There Is No Better Alternative Than TEVs to Spark Antibiotic Innovation

 
• By Francesca Bruce

Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.

EU Fines Alchem Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 
• By Eliza Slawther

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

More from Geography